• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library
    Biotech

    Aulos Bioscience`s Imneskibart Shows Clinical Activity

    BUSINESSWIRE

    Aulos Bioscience To Present Phase 2 Imneskibart (AU-007) Data

    BUSINESSWIRE

    Aulos Bioscience Presents New Phase 2 Data for AU-007 at AACR 2025

    BUSINESSWIRE

    Aulos Bioscience doses first patient in Phase 2 evaluating AU-007

    BUSINESSWIRE

    Aulos Bioscience to Present Phase 2 Data for IL-2 AU-007 at AACR

    BUSINESSWIRE

    Aulos Bioscience Doses First Patient in Phase 2 for NSCLC Treatment

    BUSINESSWIRE

    AU-007 Shows Anti-Tumor Activity in Advanced Solid Tumors at SITC

    BUSINESSWIRE

    Aulos Bioscience Presents Phase 2 Data for AU-007 at EORTC

    BUSINESSWIRE

    Aulos Bioscience Announces AU-007 Phase 2 Dose Selection

    BUSINESSWIRE

    Aulos To Present AU-007 Phase 2 Data At SITC Annual Meeting

    BUSINESSWIRE

    Aulos Au-007 Interim Positive: Phase 1/2 Data At Asco 2024

    BUSINESSWIRE

    Aulos, Merck KGaA Collaborate On Bavencio + AU-007 Combo

    BUSINESSWIRE

    First Patient Dosed in Phase 2 Portion of Aulos’ Phase 1/2 Trial for AU-007

    BUSINESSWIRE

    New Phase 1 Data for Aulos Bioscience’s AU-007 Show Favorable Pharmacodynamic

    BUSINESSWIRE

    Aulos Announces Presentation of Updated Safety and Efficacy Data From AU-007

    BUSINESSWIRE

    First U.S. Patient Dosed in Aulos Bioscience’s Phase 1/2 Trial of AU-007

    BUSINESSWIRE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.